Esperion Therapeutics (ESPR) Competitors $1.17 -0.03 (-2.50%) Closing price 04:00 PM EasternExtended Trading$1.19 +0.02 (+1.62%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. GYRE, DAWN, VIR, AVXL, ABUS, EOLS, KALV, ANAB, COGT, and ABCLShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), Evolus (EOLS), KalVista Pharmaceuticals (KALV), AnaptysBio (ANAB), Cogent Biosciences (COGT), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Its Competitors Gyre Therapeutics Day One Biopharmaceuticals Vir Biotechnology Anavex Life Sciences Arbutus Biopharma Evolus KalVista Pharmaceuticals AnaptysBio Cogent Biosciences AbCellera Biologics Esperion Therapeutics (NASDAQ:ESPR) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking. Is ESPR or GYRE more profitable? Esperion Therapeutics has a net margin of -29.37% compared to Gyre Therapeutics' net margin of -84.57%. Esperion Therapeutics' return on equity of 0.00% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-29.37% N/A -10.77% Gyre Therapeutics -84.57%-118.43%-71.97% Does the MarketBeat Community favor ESPR or GYRE? Esperion Therapeutics received 630 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 70.27% of users gave Esperion Therapeutics an outperform vote. CompanyUnderperformOutperformEsperion TherapeuticsOutperform Votes63170.27% Underperform Votes26729.73% Gyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Does the media favor ESPR or GYRE? In the previous week, Esperion Therapeutics had 7 more articles in the media than Gyre Therapeutics. MarketBeat recorded 13 mentions for Esperion Therapeutics and 6 mentions for Gyre Therapeutics. Esperion Therapeutics' average media sentiment score of 1.03 beat Gyre Therapeutics' score of 0.60 indicating that Esperion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gyre Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ESPR or GYRE? 47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 1.7% of Esperion Therapeutics shares are held by insiders. Comparatively, 10.0% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, ESPR or GYRE? Gyre Therapeutics has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$259.57M0.89-$209.25M-$0.80-1.46Gyre Therapeutics$100.64M7.44-$92.93M$0.02399.50 Which has more risk & volatility, ESPR or GYRE? Esperion Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Do analysts recommend ESPR or GYRE? Esperion Therapeutics currently has a consensus target price of $6.25, indicating a potential upside of 434.19%. Given Esperion Therapeutics' higher probable upside, equities research analysts plainly believe Esperion Therapeutics is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEsperion Therapeutics beats Gyre Therapeutics on 10 of the 18 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$231.89M$6.85B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E Ratio-1.838.4326.6419.64Price / Sales0.89262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book-0.306.536.974.60Net Income-$209.25M$143.25M$3.23B$248.06M7 Day Performance-4.10%0.21%-0.98%-1.03%1 Month Performance49.87%10.92%7.70%3.50%1 Year Performance-59.79%2.44%31.32%12.68% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics4.0553 of 5 stars$1.17-2.5%$6.25+434.2%-58.5%$231.89M$259.57M-1.83200Positive NewsAnalyst RevisionGYREGyre Therapeutics0.3177 of 5 stars$7.68-15.3%N/A-24.0%$720.06M$100.64M384.0040Short Interest ↓High Trading VolumeDAWNDay One Biopharmaceuticals1.6141 of 5 stars$7.01+9.9%$30.57+336.1%-48.5%$710.55M$161.92M-6.8160VIRVir Biotechnology2.9976 of 5 stars$5.07+2.6%$32.86+548.1%-50.2%$700.87M$14.30M-1.29580Positive NewsGap DownAVXLAnavex Life Sciences3.8723 of 5 stars$7.56+0.4%$44.00+482.0%+119.2%$645.41MN/A-13.7540Positive NewsGap DownABUSArbutus Biopharma2.2088 of 5 stars$3.36flat$5.50+63.7%+10.2%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus4.0609 of 5 stars$9.97+8.5%$23.75+138.2%-11.7%$642.83M$275.46M-10.96170Positive NewsInsider TradeHigh Trading VolumeKALVKalVista Pharmaceuticals4.0144 of 5 stars$12.92+9.5%$24.83+92.2%+6.0%$642.33MN/A-3.55100Trending NewsInsider TradeAnalyst RevisionHigh Trading VolumeANABAnaptysBio1.7625 of 5 stars$21.86-1.7%$40.38+84.7%-2.9%$642.25M$111.87M-3.60100COGTCogent Biosciences2.5119 of 5 stars$5.61+3.1%$14.57+159.7%-20.1%$638.73MN/A-2.2680Positive NewsGap DownHigh Trading VolumeABCLAbCellera Biologics2.4773 of 5 stars$2.14+5.9%$8.33+289.4%-7.9%$638.63M$23.11M-3.51500News CoverageOptions VolumeGap Down Related Companies and Tools Related Companies Gyre Therapeutics Competitors Day One Biopharmaceuticals Competitors Vir Biotechnology Competitors Anavex Life Sciences Competitors Arbutus Biopharma Competitors Evolus Competitors KalVista Pharmaceuticals Competitors AnaptysBio Competitors Cogent Biosciences Competitors AbCellera Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESPR Stock Free ESPR Stock Alerts